Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Dec;74(12):2008–2012. doi: 10.1038/bjc.1996.668

Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.

H Gabra 1, D A Cameron 1, L E Lee 1, J Mackay 1, R C Leonard 1
PMCID: PMC2074814  PMID: 8980405

Abstract

Drug scheduling alterations can improve the therapeutic index of both 5-fluorouracil and anthracyclines. We investigated a regimen of weekly doxorubicin and continuous infusional 5-fluorouracil (AcF) in loco-regionally recurrent and metastatic breast cancer. The aims of this phase II study were to use low-dose weekly anthracyclines in a patient group where liver metastases are a frequent problem, to optimise scheduling of 5-fluorouracil using continuous infusion and to conserve alkylating agent use for late intensification in responding patients. Fifty-six patients received 5-fluorouracil 200 mg m-2 day-1 and doxorubicin 20-30 mg m-2 week-1 for at least 6 weeks. Sixty-two percent were chemonaive. Patients were evaluated for dose intensity, response, toxicity and survival. Of the assessable patients, 76% achieved UICC response criteria (20% complete response, 56% partial response). WHO grade 3+ toxicities were: alopecia, 98%; mucositis, 62%; neutropenia, 22%; and grade 3 palmar-plantar syndrome, 24%. Median survival was 13 months, with visceral metastasis conferring a significantly worse outcome (P = 0.03). Grade 3+ mucositis was more frequent with planned doxorubicin dose intensity > or = 25 mg m-2 week-1 (P = 0.04). AcF is highly active in breast cancer with acceptable toxicities and can be used before alkylating agent-based high-dose therapy.

Full text

PDF
2008

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Gottdiener J. S., Appelbaum F. R., Ferrans V. J., Deisseroth A., Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981 May;141(6):758–763. [PubMed] [Google Scholar]
  2. Gregory W. M., Smith P., Richards M. A., Twelves C. J., Knight R. K., Rubens R. D. Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer. 1993 Nov;68(5):988–995. doi: 10.1038/bjc.1993.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hansen R., Quebbeman E., Beatty P., Ritch P., Anderson T., Jenkins D., Frick J., Ausman R. Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Res Treat. 1987 Nov;10(2):145–149. doi: 10.1007/BF01810577. [DOI] [PubMed] [Google Scholar]
  4. Hayward J. L., Carbone P. P., Heusen J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer. Br J Cancer. 1977 Mar;35(3):292–298. doi: 10.1038/bjc.1977.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hayward J. L., Carbone P. P., Rubens R. D., Heuson J. C., Kumaoka S., Segaloff A. Assessment of response to therapy in advanced breast cancer (an amendment) Br J Cancer. 1978 Jul;38(1):201–201. doi: 10.1038/bjc.1978.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hryniuk W. M. The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol. 1988:121–141. [PubMed] [Google Scholar]
  7. Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984 Nov;2(11):1281–1288. doi: 10.1200/JCO.1984.2.11.1281. [DOI] [PubMed] [Google Scholar]
  8. Jones R. B., Shpall E. J., Shogan J., Affronti M. L., Coniglio D., Hart L., Halperin E., Iglehart J. D., Moore J., Gockerman J. The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer. Cancer. 1990 Aug 1;66(3):431–436. doi: 10.1002/1097-0142(19900801)66:3<431::aid-cncr2820660305>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  9. Lokich J. J., Ahlgren J. D., Gullo J. J., Philips J. A., Fryer J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989 Apr;7(4):425–432. doi: 10.1200/JCO.1989.7.4.425. [DOI] [PubMed] [Google Scholar]
  10. Priestman T., Baum M., Jones V., Forbes J. Treatment and survival on advanced breast cancer. Br Med J. 1978 Dec 16;2(6153):1673–1674. doi: 10.1136/bmj.2.6153.1673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Richards M. A., Hopwood P., Ramirez A. J., Twelves C. J., Ferguson J., Gregory W. M., Swindell R., Scrivener W., Miller J., Howell A. Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. Eur J Cancer. 1992;28A(6-7):1023–1028. doi: 10.1016/0959-8049(92)90447-a. [DOI] [PubMed] [Google Scholar]
  12. Torti F. M., Bristow M. R., Howes A. E., Aston D., Stockdale F. E., Carter S. K., Kohler M., Brown B. W., Jr, Billingham M. E. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983 Dec;99(6):745–749. doi: 10.7326/0003-4819-99-6-745. [DOI] [PubMed] [Google Scholar]
  13. Twelves C. J., Dobbs N. A., Aldhous M., Harper P. G., Rubens R. D., Richards M. A. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother Pharmacol. 1991;28(4):302–307. doi: 10.1007/BF00685539. [DOI] [PubMed] [Google Scholar]
  14. Twelves C. J., O'Reilly S. M., Coleman R. E., Richards M. A., Rubens R. D. Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. Br J Cancer. 1989 Dec;60(6):938–941. doi: 10.1038/bjc.1989.394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Valdivieso M., Burgess M. A., Ewer M. S., Mackay B., Wallace S., Benjamin R. S., Ali M. K., Bodey G. P., Freireich E. J. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. J Clin Oncol. 1984 Mar;2(3):207–214. doi: 10.1200/JCO.1984.2.3.207. [DOI] [PubMed] [Google Scholar]
  16. Weiss A. J., Manthel R. W. Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer. 1977 Nov;40(5):2046–2052. doi: 10.1002/1097-0142(197711)40:5<2046::aid-cncr2820400508>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES